A Case of Perforating Folliculitis Induced by Vemurafenib

Shiraishi, Ken; Masunaga, T.; Tohyama, Mikiko; Sayama, Koji

doi:10.2340/00015555-3059

Cited by 4 publications

(3 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47,48 There is also one report each for infliximab, 49 a tumor necrosis factor inhibitor, and vemurafenib, a BRAF kinase inhibitor. 50 Based on the evidence and consent levels, the recommendation level was set as C1. Because a molecular-targeted drug (kinase inhibitor) is considered as an inducer, it is suggested that if CONFLICT OF INTEREST: None declared.…”

Section: Kyrle's Diseasementioning

confidence: 99%

“…There are four case reports on sorafenib, a multikinase inhibitor, 43–46 and two reports on nilotinib, a tyrosine kinase inhibitor 47,48 . There is also one report each for infliximab, 49 a tumor necrosis factor inhibitor, and vemurafenib, a BRAF kinase inhibitor 50 . Based on the evidence and consent levels, the recommendation level was set as C1.…”

Section: Cq Of Perforating Dermatosismentioning

confidence: 99%

See 1 more Smart Citation

Clinical practice guide for the treatment of perforating dermatosis

Kawakami

Akiyama

Ishida‐Yamamoto

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Perforating dermatoses are a heterogeneous skin disease group defined by transepidermal elimination of various skin materials. Four classical forms of primary perforating dermatosis have been described, where the transepidermal elimination mechanism represents the hallmark of the disease: acquired reactive perforating collagenosis, elastosis perforans serpiginosa, Kyrle's disease and perforating folliculitis. Acquired reactive perforating collagenosis presents with transepidermal elimination of collagen fibers. Elastosis perforans serpiginosum presents with the elimination of elastic fibers. Kyrle's disease presents with transepidermal elimination of abnormal keratin. In perforating folliculitis, it is the content of the follicle. We established diagnostic criteria and severity classification. In addition, the Japanese guideline for treatment of perforating dermatoses was updated using the Medical Information Network Distribution Service (MINDS) methodology. The guideline is based on a systematic published work review completed from 1989 to 2019, and on a formal consensus and approval process. Most medical published work on the treatment is limited to individual case reports and small series of patients. The guideline covers treatment options considered relevant by the expert panel and approved in Japan at the time of the consensus conference.

show abstract

Section: Kyrle's Diseasementioning

confidence: 99%

Section: Cq Of Perforating Dermatosismentioning

confidence: 99%

Clinical practice guide for the treatment of perforating dermatosis

Kawakami

Akiyama

Ishida‐Yamamoto

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…With the onset of immunotherapy and targeted therapy, several drugs have been implicated in reactive perforating dermatosis, including interferon [ 46 ], vemurafenib [ 47 ], erlotinib [ 48 ], and a PD-1 inhibitor [ 49 ]. Associations with immunobullous diseases have also been noted [ 50 , 51 , 52 ].…”

Section: Discussionmentioning

confidence: 99%

Perforating Gout: Expanding the Differential for Transepidermal Elimination

Bohdanowicz

Bradshaw

2023

Dermatopathology

View full text Add to dashboard Cite

Perforating dermatoses are dermatologic disorders with transepidermal elimination (TE) of dermal substances. While TE is typically associated with collagen and elastin, it can also occur as a secondary event in other processes, and it is important to keep a broad differential. We present a case of perforating tophaceous gout, which underscores the need for a thoughtful approach to perforating disorders. An updated review of recent literature is also presented.

show abstract

Vemurafenib

2019

Reactions Weekly

View full text Add to dashboard Cite

A Case of Perforating Folliculitis Induced by Vemurafenib

Cited by 4 publications

References 8 publications

Clinical practice guide for the treatment of perforating dermatosis

Clinical practice guide for the treatment of perforating dermatosis

Perforating Gout: Expanding the Differential for Transepidermal Elimination

Vemurafenib

Contact Info

Product

Resources

About